Osteopontin expressions correlate with WHO grades and predict recurrence in meningiomas.
作者： Ata Türker Arıkök , Evrim Önder , Hakan Seçkin , Ayper Kaçar , Ramazan Fesli
DOI: 10.1007/S10014-013-0152-2
关键词:
摘要: Recurrence of meningiomas is a major prognostic issue. Although World Health Organization (WHO) histopathological grading correlates strongly with recurrence, it has some limitations, and predicting the biological behavior grade I particularly difficult. Osteopontin (OPN) protein known to be involved in tumor progression. The purpose this study determine expression OPN investigate its correlation WHO grades recurrence. Immunohistochemical (IHC) evaluation was performed by two different methods ensure reliability. IHC Allred scores were calculated on basis intensity extent staining. Both agreement correlated significantly meningioma Ki-67 index. also recurrence meningiomas. Cut-off values for between non-recurrent recurrent as 70 5.5 respectively. We concluded that valuable marker tumors.
springer.com
sci-hub.se 参考文章(27)
Claudia Valentina Georgescu, Milena Georgescu, Teodora Nină, D M Pleşan, Nicoleta Pătrană, C Pleşan, Immunohistochemical evaluation of hormone receptors with predictive value in mammary carcinomas. Romanian Journal of Morphology and Embryology. ,vol. 52, pp. 1331- 1336 ,(2011)
Katrin Lamszus, Meningioma Pathology, Genetics, and Biology Journal of Neuropathology and Experimental Neurology. ,vol. 63, pp. 275- 286 ,(2004) , 10.1093/JNEN/63.4.275
David N. Louis, WHO classification of tumours of the central nervous system International Agency for Research on Cancer. ,(2007)
Arie Perry, Bernd W. Scheithauer, Scott L. Stafford, Christine M. Lohse, Peter C. Wollan, "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. ,vol. 85, pp. 2046- 2056 ,(1999) , 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M
Shiva S Forootan, Christopher S Foster, Vijay R Aachi, Janet Adamson, Paul H Smith, Ke Lin, Youqiang Ke, None, Prognostic significance of osteopontin expression in human prostate cancer International Journal of Cancer. ,vol. 118, pp. 2255- 2261 ,(2006) , 10.1002/IJC.21619
Mansoor Ahmed, Reeti Behera, Goutam Chakraborty, Shalini Jain, Vinit Kumar, Priyanka Sharma, Anuradha Bulbule, Smita Kale, Santosh Kumar, Rosalin Mishra, Remya Raja, Supriya Saraswati, Rajinder Kaur, Gowrishankar Soundararajan, Dhiraj Kumar, Dhanashri Thorat, Megha Sanyal, Anuja Ramdasi, Pompom Ghosh, Gopal C Kundu, None, Osteopontin: a potentially important therapeutic target in cancer. Expert Opinion on Therapeutic Targets. ,vol. 15, pp. 1113- 1126 ,(2011) , 10.1517/14728222.2011.594438
H Toy, O Yavas, O Eren, M Genc, C Yavas, None, Correliation Between Osteopontin Protein Expression and Histological Grade of Astrocytomas Pathology & Oncology Research. ,vol. 15, pp. 203- 207 ,(2009) , 10.1007/S12253-008-9130-0
F. Roser, M. Samii, H. Ostertag, M. Bellinzona, The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases Acta Neurochirurgica. ,vol. 146, pp. 37- 44 ,(2004) , 10.1007/S00701-003-0173-4
Daniel J. Caruso, Adrienne J.K. Carmack, Vinata B. Lokeshwar, Robert C. Duncan, Mark S. Soloway, Bal L. Lokeshwar, Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clinical Cancer Research. ,vol. 14, pp. 4111- 4118 ,(2008) , 10.1158/1078-0432.CCR-08-0738
Andrew D. Norden, Jan Drappatz, Patrick Y. Wen, Targeted drug therapy for meningiomas Neurosurgical Focus. ,vol. 23, ,(2007) , 10.3171/FOC-07/10/E12